Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer's disease

Progress in Neurobiology

Volumn 66, Issue 3, 2002, Pages 191-203

  Torreilles, François ^a   Touchon, Jacques ^b  

^a CNRS   (France)

^b GUI DE CHAULIAC HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMYLOID BETA PROTEIN; ANXIOLYTIC AGENT; ARGININE; BUSPIRONE; CALCIUM; CARBAMAZEPINE; CEREBROLYSIN; CLIOQUINOL; CORQUE; DIHYDROERGOTOXINE MESILATE; DONEPEZIL; FLUOXETINE; GALANTAMINE; HALOPERIDOL; IDEBENONE; IMIPRAMINE; INDOMETACIN; LAZABEMIDE; LITHICARB; LITHIUM; MEMANTINE; METRIFONATE; NEFAZODONE; NICERGOLINE; PAROXETINE; PHYSOSTIGMINE; PHYSOSTIGMINE SALICYLATE; PIRACETAM; PREDNISONE; RIVASTIGMINE; SELEGILINE; SERTRALINE; TACRINE; TAU PROTEIN; TETRAHYDROBIOPTERIN; THIORIDAZINE; TRAZODONE; VENLAFAXINE; VITEC;

ALZHEIMER DISEASE; AMINO ACID ANALYSIS; AUTOPSY; BIOPSY; BRAIN TISSUE; CALCIUM CELL LEVEL; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; EXTRACELLULAR SPACE; HUMAN; INFLAMMATION; MEDICAL ETHICS; NEUROPATHOLOGY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; TISSUE INJURY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ARGININE; BIOPTERIN; BRAIN; BRAIN CHEMISTRY; CALCIUM; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID PROTEINS; HUMANS; INFLAMMATION; ISOENZYMES; MODELS, BIOLOGICAL; NERVE DEGENERATION; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEUROFIBRILLARY TANGLES; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PEROXYNITROUS ACID; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SYNAPTIC TRANSMISSION; TAU PROTEINS;

EID: 0036220791     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(01)00030-2     Document Type: Review

References (153)

1. Epidemiology and risk factors of Alzheimer's disease
2. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: A community based follow-up study
3. Cerebrospinal fluid β-amyloid 1-42 in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease
4. Sensitivity, specificity, and stability of CSF tau in AD in a community-based patient sample
5. Localization of transglutaminase in hippocampal neurons: Implications for Alzheimer's disease
6. Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease
7. Neurofibrillary tangle predominant form of senile dementia of Alzheimer type: A rare subtype in very old subjects
8. Biological markers for the diagnosis of Alzheimer's disease
9. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
10. Cerebrospinal fluid lipoproteins in Alzheimer's disease
11. Alzheimer's disease and oxidative stress: Implications for novel therapeutic approaches
12. The female sex hormone oestrogen as a neuroprotectant
13. Expression analysis of BACE2 in brain and peripheral tissues
14. 100,000 Nouveaux cas de démence par an
15. Apolipoprotein E allele epsilon 4 is linked to increased deposition of the amyloid β-peptide (Aβ) in cases with or without Alzheimer's disease
16. Markers in the cerebrospinal fluid: Support of physiopathologic hypotheses
17. Alzheimer disease. Epidemiology, genetics and physiopathological hypotheses
18. Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing
19. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease
20. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients
21. Inflammatory processes induce β-amyloid precursor protein changes in mouse brain
22. Tau protein: A potential biological indicator for early detection of Alzheimer disease
23. Release of excess amyloid β-protein from a mutant amyloid β-protein precursor
24. The sulfate moieties of glycosaminoglycans are critical for the enhancement of β-amyloid protein fibril formation
25. Processing of β-amyloid precursor protein and its regulation in Alzheimer's disease
26. The Alzheimer's plaques, tangles and memory deficits may have a common origin. Part IV. Can calpain act as α-secretase?
27. The Alzheimer's plaques, tangles and memory deficits may have a common origin. Part V. Why is Ca2+ signal lower in the disease?
28. Ca2+ signaling down-regulation in ageing and Alzheimer's disease: Why is Ca2+ so difficult to measure?
29. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production
30. The role of neuronal growth factors in neurodegenerative disorders of the human brain
31. General and dramatic glial reaction in Alzheimer brains
32. Diagnosis of Alzheimer's disease
33. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease
34. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
35. Choline levels are increased in cerebrospinal fluid of Alzheimer patients
36. Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor α in cerebrospinal fluid of patients with dementia of the Alzheimer type
37. The neurobiology of somatostatin
38. Diagnosis of Alzheimer's disease with cerebrospinal fluid tau protein and aspartate aminotransferase
39. Role of endogenous nitric oxide and peroxynitrite formation in the survival and death of motor neurons in culture
40. Nitric oxide and superoxide contribute to motor neuron apoptosis induced by trophic factor deprivation
41. Nitric oxide-dependent production of cGMP supports the survival of rat embryonic motor neurons cultured with brain-derived neurotrophic factor
42. Difference in the Aβ40/Aβ42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype
43. BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein
44. Protein tau in cerebrospinal fluid of patients with Alzheimer disease
45. The cholinergic hypothesis of Alzheimer's disease: A review of progress
46. α1-Antichymotrypsin binding to Alzheimer Aβ peptides is sequence specific and induces fibril disaggregation in vitro
47. Acetylcholine in human CSF: Methodological considerations and levels in dementia of Alzheimer type
48. Age-dependent change in the levels of Aβ40 and Aβ42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Aβ42 to Aβ level in cerebrospinal fluid from Alzheimer's disease patients, and a decrease in the ratio of Aβ42 to Aβ level in cerebrospinal fluid from Alzheimer's disease patients
49. Cerebrospinal fluid levels of Aβ42 and tau: Potential markers of Alzheimer's disease
50. Cerebrospinal fluid opens a window on Alzheimer disease
51. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease
52. High cerebrospinal fluid tau and low β-amyloid 42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
53. Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients
54. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease
55. Cholinesterases and the pathology of Alzheimer disease
56. The versatile and complex enzymology of nitric oxide synthase
57. Tetrahydrobiopterin-free neuronal nitric oxide synthase: Evidence for two identical highly anticooperative pteridine binding sites
58. Neuropeptides and Alzheimer's disease
59. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease
60. Cellular and molecular basis of β-amyloid precursor protein metabolism
61. Biomarkers of Alzheimer disease
62. Detection of glutamine synthetase in the cerebrospinal fluid of Alzheimer diseased patients: A potential diagnostic biochemical marker
63. Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease
64. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease
65. Characterization of Alzheimer's β-secretase protein BACE. A pepsin family member with unusual properties
66. Alzheimer's disease lesions: From morphology to cell biology
67. Nitric oxide, mitochondria and neurological disease
68. Cerebrospinal fluid nitrite plus nitrate correlates with tetrahydrobiopterin concentration
69. Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia
70. Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase
71. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial
72. Biological markers of Alzheimer's disease
73. Increased CSF levels of nerve growth factor in patients with Alzheimer's disease
74. Early-onset Alzheimer's disease due to mutations of the presenilin-1 gene on chromosome 14: A 7 years follow-up of a patient with a mutation at codon 139
75. Elevated levels of tau and ubiquitin in brain and cerebrospinal fluid in Alzheimer's disease
76. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease
77. Cerebrospinal-fluid tau protein and aspartate aminotransferase in Parkinson's disease
78. Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression
79. Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease
80. The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments
81. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF
82. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42/43 in Alzheimer's disease: A study in Japan
83. Diagnostic markers for Alzheimer's disease
84. Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease
85. Stimulation of human nitric oxide synthase by tetrahydrobiopterin and selective binding of the cofactor
86. Biological markers of Alzheimer's disease
87. Plasma neuropeptide Y is reduced in patients with Alzheimer's disease
88. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease
89. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: Interleukin-1β, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-α, the soluble tumor necrosis factor receptors I and II, and α1-antichymotrypsin
90. Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease
91. Recent advances in the genetics of Alzheimer's disease
92. Increased serum α1-antichymotrypsin in patients with probable Alzheimer's disease: An acute phase reactant without the peripheral acute phase response
93. Acute phase reactant α1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease
94. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments
95. Tau in Alzheimer's disease
96. Oxidative alterations in Alzheimer's disease
97. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau
98. Nitric oxide synthase-catalyzed activation of oxygen and reduction of cytochromes: Reaction mechanisms and possible physiological implications
99. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases
100. Anti-inflammatory drugs and Alzheimer disease
101. Interactions of Alzheimer amyloid β-peptides with glycosaminoglycans effects on fibril nucleation and growth
102. Tau protein in cerebrospinal fluid: A new diagnostic and prognostic marker in Alzheimer disease
103. Plasma and cerebrospinal fluid levels of amyloid β-proteins 1-40 and 1-42 in Alzheimer disease
104. Tau and ApoE in CSF: Potential aid for discriminating Alzheimer's disease from other dementias
105. Reappraising neurotransmitter-based strategies
106. Increased CSF F2-isoprostane concentration in probable AD
107. Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease
108. Cerebrospinal fluid Aβ42, tau, and F2-isoprostane concentrations in patients with Alzheimer disease, and F2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls
109. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments
110. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4
111. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial: Alzheimer's disease cooperative study
112. The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease
113. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: Multicenter study in Japan
114. Cerebrospinal fluid epinephrine in Alzheimer's disease and normal aging
115. α1-Antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer's disease
116. Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease
117. Detection of single amyloid β-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy
118. Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo
119. Brain iron and neurological disorders
120. Diagnosis of Alzheimer's disease with cerebrospinal fluid tau protein and aspartate aminotransferase
121. Cerebrospinal β-amyloid 1-42 in early Alzheimer's disease: Association with apolipoprotein E genotype and cognitive decline
122. Mild cognitive impairment: Conceptual basis and current nosological status
123. Some remarks on biological markers of Alzheimer's disease
124. Apolipoprotein E alleles as risk factors in Alzheimer's disease
125. Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: Impact on non-Alzheimer's dementia
126. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease
127. CSF β-amyloid, cognition, and ApoE genotype in Alzheimer's disease
128. Modeling of substrat specificity of the Alzheimer's disease amyloid precursor protein β-secretase
129. Genes and susceptible loci of Alzheimer's disease
130. Combination assay of CSF tau, Aβ1-40 and Aβ1-42/43 as a biochemical marker of Alzheimer's disease
131. Protective action of 17β-estradiol and tamoxifen on glutamate toxicity in glial cells
132. Strategies that support declining cholinergic neurotransmission in Alzheimer's disease patients
133. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease
134. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-old: Relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele
135. Tau protein directly interacts with the amyloid β-protein precursor: Implications for Alzheimer's disease
136. Assessment of amyloid β-protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease
137. Apolipoprotein E and Alzheimer's disease
138. Increased aspartate aminotransferase activity in cerebrospinal fluid and Alzheimer's disease
139. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease
140. Three years follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease
141. Genetic risk factors in Alzheimer's disease
142. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia
143. The cerebrospinal fluid oxidized NO metabolites, nitrite and nitrate, in Alzheimer's disease and vascular dementia of Binswanger type and multiple small infarct type, in Alzheimer's disease and vascular dementia of Binswanger type and multiple small infarct type
144. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis
145. Neurodegenerative disorders: The role of peroxynitrite
146. Glutamine synthetase in cerebrospinal fluid, serum, and brain: A diagnostic marker for Alzheimer disease
147. The cause of neuronal degeneration in Alzheimer's disease
148. Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia
149. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury
150. Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy
151. Apolipoprotein E in cerebrospinal fluid: Relation to phenotype and plasma apolipoprotein E concentrations
152. Nitric oxide synthase neurons in different areas of normal aged and Alzheimer's brains
153. The role of Aβ42 in Alzheimer's disease